Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
Journal of Managed Care & Specialty Pharmacy|June 29, 2018
Reframing the Value of Treatments for Relapsed/Refractory Multiple MyelomaSikander Ailawadhi, Sumeet Panjabi, Marco Campioni, et al.Therapeutic Advances in Hematology|July 19, 2021
The value of survival gains from therapeutic innovations for US patients with relapsed/refractory multiple myelomaJoanna P MacEwan, Istvan Majer, Jacquelyn W Chou, et al.BMC Musculoskeletal Disorders|August 3, 2017
Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysisThomas Wilke, Sabrina Mueller, Sze Chim Lee, et al.Rheumatology International|July 13, 2015
A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilizationPaul Emery, Caitlyn Solem, Istvan Majer, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 2, 2022
Estimating and Extrapolating Survival Using a State-Transition Modeling Approach: A Practical Application in Multiple MyelomaIstvan Majer, Sonja Kroep, Rana Maroun, et al.Journal of Managed Care & Specialty Pharmacy|August 29, 2019
Letter--Value-Driven Treatment Decisions: Need of the Hour for Relapsed/Refractory Multiple MyelomaRohan Medhekar, Sandhya J Sapra, Istvan Majer, et al.Applied Health Economics and Health Policy|August 24, 2016
Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level DataIstvan Majer, Gijs van de Wetering, Zoltan Polanyi, et al.Expert Review of Hematology|April 7, 2020
Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United StatesShaji K Kumar, Istvan Majer, Sumeet Panjabi, et al.Health Economics Review|December 21, 2017
Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in SpainRalph Schmidt, Istvan Majer, Natalia García Román, et al.Journal of Managed Care & Specialty Pharmacy|June 24, 2026
Real-world treatment patterns, resource use, and costs in human epidermal growth factor receptor 2-negative advanced gastric/gastroesophageal junction cancer in the United States in the immune checkpoint inhibitor eraZiyan Chen, Wei Song, Jenna Abdelhadi, et al.Pageof 2